Crescent Biopharma, Inc.
CBIO
$10.50
$0.151.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -92.40M | -24.61M | -21.79M | ||
| Total Depreciation and Amortization | 54.00K | 28.00K | 2.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 84.84M | 2.08M | 7.55M | ||
| Change in Net Operating Assets | -19.24M | 4.96M | -2.16M | ||
| Cash from Operations | -26.74M | -17.54M | -16.40M | ||
| Capital Expenditure | -193.00K | -586.00K | -140.00K | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -72.00M | -- | -- | ||
| Cash from Investing | -72.19M | -586.00K | -140.00K | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 178.86M | -- | 144.28M | ||
| Repurchase of Common Stock | 0.00 | -1.25M | -177.00K | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | 0.00 | 0.00 | 2.76M | ||
| Cash from Financing | 178.86M | -1.25M | 146.86M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 79.93M | -19.38M | 130.32M | ||